Skye Bioscience Inc.(US:SKYE) Prnewswire·2025-12-04 15:55Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Skye Biosciences, Inc. due to allegations of misleading statements regarding the effectiveness of its drug nimacimab, which led to significant stock price declines [2][4]. Group 1: Legal Investigation - Faruqi & Faruqi is encouraging investors who suffered losses in Skye to contact them for discussing legal options [1]. - A federal securities class action has been filed against Skye, with a deadline of January 16, 2026, for investors to seek the role of lead plaintiff [2][6]. - The firm has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [3]. Group 2: Allegations Against Skye - The complaint alleges that Skye and its executives violated federal securities laws by making false statements about nimacimab's effectiveness and overstating its clinical and commercial prospects [4]. - On October 6, 2025, Skye announced that nimacimab did not achieve its primary endpoint in a clinical study, leading to a 60% drop in stock price, closing at $1.90 per share [5]. Group 3: Investor Participation - The lead plaintiff in the class action will be the investor with the largest financial interest who is also typical of class members [6]. - Any member of the putative class can move the court to serve as lead plaintiff or choose to remain an absent class member without affecting their ability to share in any recovery [6]. Group 4: Additional Information - Faruqi & Faruqi is also seeking information from whistleblowers, former employees, and shareholders regarding Skye's conduct [7].